In particular, Akt/Tor signaling contributes to the increased cell survival in APL, and, consequently, dual therapy with PI3K inhibitors and retinoids has shown great therapeutic promise [113]. This evidence concerns the gene AKT1 and acute promyelocytic leukemia.